Powell B L, Gregory B W, Kute T E, Morgan T M, Lyerly E S, Capizzi R L
Cancer Center, Wake Forest University, Winston-Salem, North Carolina 27103.
Cytometry. 1990;11(3):438-41. doi: 10.1002/cyto.990110315.
Leukemia blasts isolated from bone marrow aspirates of 44 adults with acute leukemia were incubated for 1 h with 0.008-32 microM bromodeoxyuridine (Brd-Urd). After dual labeling with monoclonal anti-BrdUrd antibodies and propidium iodide, the cells were analyzed by flow cytometry. Percent labeled cells and intensity of labeling were similar over concentrations of BrdUrd ranging from 0.8-32 microM--a 40-fold range. Therefore, despite potential interpatient variability in nucleoside pharmacokinetics, commonly used doses of BrdUrd which are intended to achieve steady-state plasma concentrations in the 8.0 microM range can be expected to provide a reliable estimate of the S-phase fraction.
从44例成年急性白血病患者的骨髓穿刺物中分离出的白血病原始细胞，与0.008 - 32微摩尔的溴脱氧尿苷（Brd - Urd）一起孵育1小时。用单克隆抗BrdUrd抗体和碘化丙啶进行双重标记后，通过流式细胞术分析细胞。在0.8 - 32微摩尔的BrdUrd浓度范围内（40倍的范围），标记细胞的百分比和标记强度相似。因此，尽管患者之间核苷药代动力学可能存在差异，但旨在达到8.0微摩尔范围内稳态血浆浓度的常用剂量的BrdUrd有望提供可靠的S期分数估计值。
